tubulin inhibitor 11

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

C-11 is a tubulin inhibitor and functions as an ADC cytotoxin, exhibiting cytotoxicity for carcinoma cell lines.

Tubulin inhibitor 7 is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines (tubulin polymerization (IC50: 0.52 μM), K562 cell growth (IC50: 11 nM)).

Tubulin polymerization-IN-74 (compound 11) is an inhibitor of tubulin polymerization, with an IC50 value of 15 μM. It is applicable to cancer research.

HDAC6-IN-47 (Compound S-29b) is an HDAC inhibitor with high affinity for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10, with Ki values of 60, 56, 162, 0.44, 362, and 849 nM, respectively. It induces hyperacetylation of tubulin in MV4-11 cells and inhibits their proliferation with an EC50 of 0.50 µM. HDAC6-IN-47 is applicable in leukemia research.

Microtubule inhibitor 11 (compound 33) is a tubulin inhibitor with a mechanism of action similar to that of colchicine. It is utilized in cancer-related research.

Tubulin inhibitor 45 (compound 5) functions as an inhibitor of the active site of tubulin. It exhibits IC50 values of 11 μM for MCF7 cancer cells and 13 μM for HePG2 cancer cells.

Tubulin aggregation-IN-20 (compound 11) is a potent tubulin aggregation inhibitor with potential applications in the investigation of breast and drug-resistant colon cancer.

MC-EVCit-PAB-MMAE (Linker-Payload 11), a conjugate used in antibody-drug conjugates (ADCs), consists of the MC-EVCit-PAB linker connected to the potent tubulin polymerization inhibitor MMAE [1].